Nishiyama, Hiroyuki
Yamamoto, Yoshiaki
Sassa, Naoto
Nishimura, Kazuo
Fujimoto, Kiyohide
Fukasawa, Satoshi
Yokoyama, Minato
Enokida, Hideki
Takahashi, Kenichi
Tanaka, Yoshinobu
Imai, Kentaro
Shimamoto, Takashi
Perini, Rodolfo
Frenkl, Tara
Bajorin, Dean
Bellmunt, Joaquim
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Article History
Received: 10 July 2019
Accepted: 6 September 2019
First Online: 15 November 2019
Compliance with ethical standards
:
: HN: No conflicts to disclose. YY: No conflicts to disclose. NS: No conflicts to disclose. KN: Received lecture fees from Astellas and Novartis. KF: No conflicts to disclose. SF: Received research funding from Merck. MY: No conflicts to disclose. HE: No conflicts to disclose. KT: Employee of MSD K.K., Tokyo, Japan. Stockholder of Merck & Co., Inc., Kenilworth, NJ, USA. YT: Employee of MSD K.K., Tokyo, Japan. Stockholder of Merck & Co., Inc., Kenilworth, NJ, USA. KI: Employee of MSD K.K., Tokyo, Japan. Stockholder of Merck & Co., Inc., Kenilworth, NJ, USA. TS: Employee of MSD K.K., Tokyo, Japan. Stockholder of Merck & Co., Inc., Kenilworth, NJ, USA. RP: Employee and stockholder of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. TF: Employee and stockholder of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. DB: Served in an advisory role for Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech, Fidia Farmaceutici, Roche, Merck, Eli Lilly, received fees for promotional materials from Merck, received research funding from Merck and other (eg trips, travel or gifts) from Eli-Lilly. JB: Served in an advisory role for Genentech, Merck, AstraZeneca, and Bristol-Myers Squibb, patent royalties from UpToDate, honoraria from Merck and Bristol-Myers Squibb, research funding from Pfizer, and MSD Serono, and other (trips, travel or gifts) from Pfizer and Ipsen.